Document Classification

Section Type: RESULTS

Text: From the run-in period to week 48, both treatments improved symptoms (mean change -159 [-194 to -125] in the as-needed beclometasone-formoterol group vs -144 [-178 to -110] in the as-needed salbutamol group, difference -015 [-060 to 030] ; p = 0507), percentage of asthma control days (95 % [73 to 118] vs 109 % [87 to 131], respectively, -14 [-43 to 16] ; p = 0359), use of reliever (-029 [-038 to -020] vs -027 [-036 to -019], respectively, -002 [-013 to 010] ; p = 0794), and lung function (FEV1, 0090 [0060 to 0120] vs 0090 [0060-0120], respectively, 0001 [-0040 to 0040] ; p = 0969), and were well tolerated (patients with serious adverse events, 32 [4 %] and 41 [5 %], respectively).